Johannes Kepler University
- Address
- Med Campus III, Krankenhausstrasse 9, 4020 Linz, Austria
Cardiovascular Diseases Research
At Johannes Kepler University in Linz, the Department of Surgery Division of Cardiac Surgery is involved in studies focused on cardiovascular diseases, especially coronary artery disease. The trials are designed to assess whether new treatment strategies can improve heart-related outcomes and reduce complications after surgery.
- Evaluating a treatment approach for patients undergoing coronary artery bypass grafting
- Studying ways to lower the risk of ischemic events and graft failure
- Comparing the effectiveness of different antiplatelet strategies
These investigations aim to improve recovery, long-term protection, and overall treatment effectiveness in people with serious heart disease.
Neoplasms Research
The site is also contributing to clinical research in neoplasms, with a strong focus on melanoma and Ewing sarcoma. The goal of this work is to test new cancer treatment strategies and improve survival outcomes for patients with advanced or high-risk disease.
- Testing a new therapy approach for previously treated advanced melanoma
- Exploring treatment optimization in Ewing sarcoma
- Assessing whether therapy combinations can improve overall survival and event-free survival
These studies reflect an active effort to refine cancer care and identify more effective options for difficult-to-treat tumors.
Hormonal Diseases Research
Clinical trials in hormonal diseases at this educational institution include research on growth hormone deficiency. The main purpose is to better understand treatment effects on growth outcomes and how closely patients can reach their expected adult height.
- Studying growth hormone deficiency in children and adolescents
- Comparing growth-related outcomes between treatment groups
- Evaluating whether therapy can improve final height results
This research helps clarify the impact of treatment on growth and supports more personalized care for patients with endocrine disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 14 therapeutic areas and 15 of 152 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 140 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 35 by active trials.
- 1Janssen Cilag International4active
lock +34 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG6trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Johannes Kepler University
lock Showing 1 of 76 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis | Cogent Biosciences Inc. | Phase II | Not Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 152 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 8 | Unknown | 2015-05-05 | 2026-06-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.